AIGH Capital Management LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 345,000 shares of the company’s stock, valued at approximately $1,533,000. AIGH Capital Management LLC owned 9.24% of Aprea Therapeutics at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the stock. Sio Capital Management LLC acquired a new stake in Aprea Therapeutics during the first quarter valued at approximately $1,243,000. Jane Street Group LLC acquired a new stake in Aprea Therapeutics during the second quarter valued at approximately $54,000. BNP Paribas Arbitrage SNC acquired a new stake in Aprea Therapeutics during the third quarter valued at approximately $40,000. Millennium Management LLC lifted its stake in Aprea Therapeutics by 35.7% during the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock valued at $53,000 after purchasing an additional 43,293 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Aprea Therapeutics by 5.7% during the first quarter. Renaissance Technologies LLC now owns 297,900 shares of the company’s stock valued at $554,000 after purchasing an additional 15,977 shares during the last quarter. 23.62% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms recently commented on APRE. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research note on Thursday, August 10th. Wedbush restated an “outperform” rating and issued a $9.00 price target on shares of Aprea Therapeutics in a research report on Thursday, August 10th.
Aprea Therapeutics Stock Performance
Shares of NASDAQ:APRE traded up $0.09 during mid-day trading on Friday, hitting $3.97. The stock had a trading volume of 6,933 shares, compared to its average volume of 10,592. The company has a market cap of $14.84 million, a PE ratio of -0.72 and a beta of 0.84. Aprea Therapeutics, Inc. has a 12-month low of $2.78 and a 12-month high of $20.75. The company’s 50 day moving average is $3.50 and its 200-day moving average is $3.90.
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.56. The firm had revenue of $0.25 million during the quarter. On average, equities research analysts predict that Aprea Therapeutics, Inc. will post -3.26 EPS for the current fiscal year.
About Aprea Therapeutics
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.
- Five stocks we like better than Aprea Therapeutics
- How to Start Investing in Real Estate
- MarketBeat Week in Review – 9/4 – 9/8
- How to Invest in Music Stocks
- The Best 5 Small Cap AI Companies to Buy Now
- How to Invest and Trade Chinese Stocks
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.